Analyst Price Targets — WGS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 5, 2026 12:09 pm | Bill Bonello | Craig-Hallum | $85.00 | $35.59 | TheFly | GeneDx price target lowered to $85 from $153 at Craig-Hallum |
| May 5, 2026 11:35 am | — | BTIG | $90.00 | $67.93 | TheFly | GeneDx price target lowered to $90 from $170 at BTIG, removed from Top Picks |
| May 5, 2026 11:21 am | — | Guggenheim | $70.00 | $67.93 | TheFly | GeneDx price target lowered to $70 from $100 at Guggenheim |
| May 5, 2026 10:46 am | Kyle Mikson | Canaccord Genuity | $75.00 | $67.93 | TheFly | GeneDx price target lowered to $75 from $100 at Canaccord |
| May 5, 2026 10:20 am | Brandon Couillard | Wells Fargo | $75.00 | $67.93 | TheFly | GeneDx price target lowered to $75 from $155 at Wells Fargo |
| April 20, 2026 1:08 pm | — | Canaccord Genuity | $100.00 | $67.72 | TheFly | GeneDx price target raised to $100 from $70 at Canaccord |
| February 24, 2026 12:45 pm | Mark Massaro | BTIG | $170.00 | $87.08 | TheFly | GeneDx price target lowered to $170 from $200 at BTIG |
| February 24, 2026 11:41 am | David Westenberg | Piper Sandler | $130.00 | $87.08 | TheFly | GeneDx price target lowered to $130 from $160 at Piper Sandler |
| February 23, 2026 8:49 pm | — | Jefferies | $150.00 | $87.08 | TheFly | GeneDx price target lowered to $150 from $180 at Jefferies |
| December 22, 2025 12:03 pm | — | Canaccord Genuity | $170.00 | $140.44 | TheFly | GeneDx price target raised to $170 from $160 at Canaccord |
Latest News for WGS
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating GeneDX Holdings Corp. (NYSE: WGS) for potential securities law violations. Investors who have lost money in their GeneDX Holdings Corp. investment should contact the firm to learn more about how they might recover those losses.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON GENEDX HOLDINGS CORP. (WGS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is the…
MILWAUKEE, May 5, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against GeneDx (Nasdaq: WGS). The investigation results from inaccurate statements GeneDx may have made regarding its financial statements, business operations and prospects.
GeneDX's latest quarterly report arrived with a lot of bad news for investors.
GeneDx stock crashed Tuesday on what one analyst called its "alarming" first-quarter sales miss, leading to a guidance cut for the year.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for WGS.
U.S. House Trading
No House trades found for WGS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.